Latest chronic lymphocytic leukemia Stories
Oral Presentation at the American Association of Cancer Research Annual Meeting PHILADELPHIA, April 20, 2015 /PRNewswire/ -- Pharmacyclics, Inc.
New IMBRUVICA Data from National Institutes of Health Study Published in The Lancet Oncology SUNNYVALE, Calif., Jan. 5, 2015 /PRNewswire/ -- Pharmacyclics, Inc.
IMBRUVICA data presented at the American Society of Hematology Annual Meeting show 79 percent of CLL patients with del 17p were progression-free at 12 months SAN FRANCISCO and RARITAN, N.J.,
Data Show 84% Progression-Free Survival Rate at One Year and Improvement in Quality of Life SAN FRANCISCO, Dec. 8, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
U.S.-Based Registry Will Enhance Clinical Knowledge of and Explore Treatment Options for CLL Patients SUNNYVALE, Calif., Dec. 5, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
SUNNYVALE, Calif., Dec.
Health Canada approves GAZYVA((TM)) (obinutuzumab), a medicine that harnesses the body's immune system to kill cancer cells, for patients with chronic lymphocytic leukemia (or CLL)
Data from 13 accepted abstracts include: NORTH CHICAGO, Ill., Nov.
Additional test for susceptibility in certain types of lymphoma FT. MYERS, Fla., Oct. 23, 2014 /PRNewswire/ -- NeoGenomics, Inc.
Approval based on Phase 3 RESONATE data with statistically significant improvements in progression-free and overall survival HORSHAM, Pa., July 28, 2014 /PRNewswire/ -- The U.S.
- Growing in low tufty patches.